Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brandeis University

www.brandeis.edu/osp

Latest From Brandeis University

MeiraGTx Signs J&J To Develop Gene Therapies For Rare Retinal Diseases

While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the global reach to expedite its program in inherited retinal diseases, including three clinical candidates.

Deals Commercial

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.

StartUps and SMEs Financing

VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion

Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.

Commercial Companies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register